研究疾病:
|
子宫内膜异位症继发性痛经
|
研究疾病代码:
|
|
Target disease:
|
Dysmenorrhea secondary to endometriosis
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
其它
Others
|
研究目的:
|
揭示痛经宁巴布剂结合中医外治法经络学说改善血瘀型子宫内膜异位症相关性痛经临床疗效,开发一种新的诊疗技术,建立新的诊疗方案。
|
Objectives of Study:
|
Objective to explore the clinical effect of Tongjingning cataplasm combined with meridian theory of external treatment of traditional Chinese medicine on dysmenorrhea related to endometriosis of blood stasis type, develop a new diagnosis and treatment technology, and establish a new diagnosis and treatment scheme.
|
药物成份或治疗方案详述:
|
痛经宁巴布剂;用法:外用贴敷于以关元为中心,横向为14cm,纵向为10cm皮肤、1贴/天,连用14天为1个疗程,连续治疗3个疗程。(研究药物由江苏天江药业股份有限公司提供,同时提供相应批号的药检合格报告。药品需保存在密封、干燥处。)痛经宁组成:生蒲黄包18g、大红藤30g、制乳没各3g、田三七粉2g、威灵仙18g、柴胡9g、延胡9g、刘寄奴9g、葫芦巴18g)。
|
Description for medicine or protocol of treatment in detail:
|
Tongjingning cataplasm; usage: topical application to Guanyuan as the center, horizontal 14cm, vertical 10cm skin, 1 paste / day, continuous use for 14 days as a course of treatment, continuous treatment for 3 courses. (the study drug was provided by Jiangsu Tianjiang Pharmaceutical Co., Ltd., and the drug inspection report of corresponding batch number was provided. Keep the medicine in a sealed and dry place.) Tongjingning: raw puhuangbao 18G, dahongteng 30g, zhirumei 3G, tiansanqi powder 2G, Clematis 18G, bupleurum 9g, Yanhu 9g, liujinu 9g, Huluba 18G).
|
纳入标准:
|
(1)符合子宫内膜异位症西医临床或病理诊断标准;
(2)符合中医子宫内膜异位症血瘀证诊断标准;
(3)年龄在25-48岁之间,非哺乳期患者;
(4)月经周期规律者(月经周期21-35天);
(5)自愿签署知情同意书。
|
Inclusion criteria
|
(1) They were in accordance with the clinical or pathological diagnostic criteria of endometriosis;
(2) It was consistent with the diagnostic criteria of blood stasis syndrome of endometriosis;
(3) Non lactation patients aged 25-48 years old;
(4) Regular menstrual cycle (menstrual cycle 21-35 days).
(5) Voluntary informed consent.
|
排除标准:
|
(1)经检查证实由妇科肿瘤(子宫肌瘤小于3cm者除外)、特异性阴道炎(外阴阴道假丝酵母菌病、滴虫性阴道炎、细菌性阴道炎等)、子宫腺肌病、结核性盆腔炎、盆腔脓肿、盆腔肿物、宫颈病变等其它病症引起相关症状者;
(2)子宫缺如和/或双附件缺如者;
(3)妊娠期或半年内准备妊娠妇女,哺乳期妇女;
(4)合并有严重心、脑血管、肝、肾及造血系统、糖尿病、甲状腺疾病等严重原发性疾病、精神病患者;
(5)过敏体质,以及对本药相关成份过敏者;
(6)近一个月内参与其它临床研究者,或一个月内正采用同类药物及相关治疗,如服用过相关或拮抗作用的药物(如抗生素),致药物疗效难以判断者;
(7)怀疑或确认有酒精成瘾、药物滥用病史,或者根据研究者的判断,具有降低入组可能性或使入组复杂化的其他病变或情况,如工作环境经常变动、生活环境不稳定等易造成失随访的情况;
(8)研究者认为不适宜参加本临床试验者。
|
Exclusion criteria:
|
(1) It was confirmed by examination that it was composed of gynecological tumor (except uterine fibroids less than 3cm), specific vaginitis (vulvovaginal Candida)
In addition, there are many diseases, such as trichomonal vaginitis, bacterial vaginitis, adenomyosis, tuberculous pelvic inflammatory disease, pelvic abscess, pelvic mass and cervical disease
Other diseases such as dysplasia cause related symptoms;
(2) Absence of uterus and / or double appendages;
(3) Pregnant or half a year pregnant women, lactating women;
(4) They were complicated with serious primary diseases such as heart, cerebrovascular, liver, kidney and hematopoietic system, diabetes, thyroid diseases and mental disorders
Patients with chronic hepatitis B;
(5) Allergic constitution, as well as allergic to the relevant components of the drug;
(6) Those who have participated in other clinical studies in the past month, or are taking similar drugs and related treatments in the past month, such as taking related drugs or
Antagonistic drugs (such as antibiotics) make it difficult to judge the efficacy of drugs;
(7) Suspected or confirmed to have a history of alcohol addiction or drug abuse, or according to the judgment of the researcher, with the possibility of reducing the enrollment or making the
Other complicated diseases or conditions, such as frequent changes in working environment and unstable living environment, are likely to cause loss of follow-up;
(8) The researcher thinks that it is not suitable to participate in this clinical trial.
|
研究实施时间:
Study execute time:
|
从From
2021-11-01
至To
2023-11-30
|
征募观察对象时间:
Recruiting time:
|
从From
2021-11-01
至To
2023-02-22
|